Bristol-Myers Squibb says open label outpatient switch study demonstrates symptom stability during transition from oral atypical antipsychotics to Cobenfy

AI BRIEFING

• ⬤ Study shows patients with schizophrenia or bipolar disorder maintain symptom stability after switching from oral atypical antipsychotics to Cobenfy, a subcutaneous injectable treatment.
• ⬤ The open-label study involved 176 patients who received Cobenfy for at least 6 months and showed no significant changes in symptoms.
• ⬤ Results suggest Cobenfy may offer an effective treatment option for patients who have difficulty adhering to oral medications.